Overactive Bladder and Gemtesa (Vibregon)

June 11, 2021

Overactive bladder (OAB) is a common medical condition affecting as many as 30 percent of men and 40 percent of women in the United States. It is estimated that up to 50 percent of women and 30 percent of men will have bladder control problems during their lifetime.

OAB is characterized by a sudden, uncomfortable need to urinate with or without urine leakage usually with daytime and nighttime frequency. OAB occurs when the smooth muscles of the detrusor muscle of the bladder squeezes or contracts more often than normal and at inappropriate times. Instead of staying at rest as urine fills the bladder, the detrusor contracts while the bladder is filling with urine.

Often, lifestyle changes can improve symptoms. But if these fail there are medical options, as well.

There are multiple medications that are used to treat OAB. And now there’s a new one.

Meet Gemtesa® (vibregon).

Gemtesa is a medication that lives in a class of overactive bladder medications called “beta-agnoists.” These medications help relax the bladder muscle so it can hold more urine. This reduces the urgency and frequency and leaking.

In studies, about half of people taking Getesa saw a 75% or greater reduction in symptoms after three months of use and less than 2% of people stopped taking it due to side effects.

If you’ve tried lifestyle modifications and other medications to help control your OAB symptoms and have not had relief, call Austin Urology Institute to schedule a consultation with a provider and to discuss if Gemtesa is an alternative.